IMV · IMV Inc.

-

Please sign in to comment on IMV

1 Comment

Admin

4 years ago

IMV Inc is currently in a long term downtrend where the price is trading 33.4% below its 200 day moving average.

From a valuation standpoint, the stock is 6017.4% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 81933.1.

IMV Inc's total revenue sank by 100.0% to $0 since the same quarter in the previous year.

Its net income has dropped by 13.2% to $-10M since the same quarter in the previous year.

Finally, its free cash flow fell by 2.0% to $-8M since the same quarter in the previous year.

Based on the above factors, IMV Inc gets an overall score of 0/5.

Exchange	NASDAQ
CurrencyCode	USD
ISIN	CA44974L1031
Sector	Healthcare
Industry	Biotechnology

Dividend Yield	0.0%
Market Cap	10M
Beta	1.52
PE Ratio	None
Target Price	38.33

ABOUT

IMV Inc.

IMV Inc. operates as a clinical-stage immuno-oncology company. The company develops a portfolio of therapies based on DPX its immune-educating technology platform for treatment of solid and hematological cancers. The company's lead drug candidate includes maveropepimut-S, a DPX-based immunotherapy that targets survivin-expressing cells that is Phase II clinical trials for diffuse large B cell lymphoma; ovarian cancer; and bladder, liver, and MSI-H solid tumors, as well as in Phase I clinical trial for breast cancer. It also develops DPX-SurMAGE that is in Phase I clinical trial for bladder cancer; and DPX-COVID-19 and DPX-RSV for infectious diseases. The company was formerly known as Immunovaccine Inc. and changed its name to IMV Inc. in May 2018. IMV Inc. was founded in 2000 and is headquartered in Dartmouth, Canada.

IMV · IMV Inc.

-

IMV Inc.

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest IMV Inc. using a moving average strategy